Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume - What's Next?

Oculis Holding AG (NASDAQ:OCS - Get Free Report) saw unusually-high trading volume on Friday . Approximately 63,615 shares changed hands during mid-day trading, an increase of 48% from the previous session's volume of 43,047 shares.The stock last traded at $18.10 and had previously closed at $17.40.

Analysts Set New Price Targets

Several analysts have weighed in on OCS shares. HC Wainwright lifted their price objective on Oculis from $29.00 to $32.00 and gave the company a "buy" rating in a research report on Thursday, April 17th. Chardan Capital restated a "buy" rating and issued a $28.00 price objective on shares of Oculis in a report on Thursday, April 17th. Finally, Robert W. Baird raised their price target on shares of Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a report on Thursday, March 13th.

Oculis Stock Up 3.3 %

The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $18.04 and a 200-day simple moving average of $18.32. The firm has a market cap of $830.89 million, a P/E ratio of -9.86 and a beta of 0.27.

Oculis (NASDAQ:OCS - Get Free Report) last released its earnings results on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. On average, equities analysts anticipate that Oculis Holding AG will post -2.09 earnings per share for the current year.

Institutional Investors Weigh In On Oculis

Institutional investors and hedge funds have recently bought and sold shares of the business. Bellevue Group AG purchased a new stake in shares of Oculis during the fourth quarter worth about $170,000. XTX Topco Ltd purchased a new stake in Oculis during the 4th quarter valued at approximately $225,000. Kestra Private Wealth Services LLC bought a new stake in shares of Oculis during the first quarter valued at approximately $234,000. Geode Capital Management LLC lifted its holdings in shares of Oculis by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after buying an additional 1,800 shares in the last quarter. Finally, Citadel Advisors LLC bought a new position in shares of Oculis during the fourth quarter worth $389,000. 22.30% of the stock is owned by institutional investors.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.